Given that dimerization and enhanced EGFR-RAS signalling drives pathway reactivation, we reasoned that PLX8394 may be a more effective BRAF inhibitor in BRAF mutant CRC for use in combination therapy. Here, EGFR is linked to colorectal carcinoma.